Publicaciones en las que colabora con P. Jiménez Fonseca (35)

2024

  1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787

  2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  3. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  5. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  6. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

  7. State of the scientific evidence and recommendations for the management of older patients with gastric cancer

    Journal of Geriatric Oncology, Vol. 15, Núm. 3

2023

  1. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study

    Oncologist, Vol. 28, Núm. 11, pp. 986-995

  2. Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer

    Psycho-Oncology, Vol. 32, Núm. 11, pp. 1694-1701

  3. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  4. Mental Adjustment, Functional Status, and Depression in Advanced Cancer Patients

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 4

  5. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

  6. Psychological factors and prognostic communication preferences in advanced cancer: multicentre study

    BMJ Supportive and Palliative Care, Vol. 13, Núm. e3, pp. E1342-E1350

  7. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

  8. The Relationship between Therapeutic Alliance and Quality of Care in Patients with Advanced Cancer in Spain

    Current Oncology, Vol. 30, Núm. 4, pp. 3580-3589

  9. The Role of Financial Difficulties as a Mediator between Physical Symptoms and Depression in Advanced Cancer Patients

    Current Oncology, Vol. 30, Núm. 6, pp. 5719-5726

  10. Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors

    Current Oncology, Vol. 30, Núm. 10, pp. 9205-9216

  11. Using the emotional functioning in clinical practice to detect psychological distress in patients with advanced thoracic and colorectal cancer

    Health and Quality of Life Outcomes, Vol. 21, Núm. 1

  12. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491

2022

  1. Dignity and psychosocial related variables in elderly advanced cancer patients

    BMC Geriatrics, Vol. 22, Núm. 1